Xilio Therapeutics elects Dr. Akintunde Bello to Board of Directors

Xilio Therapeutics, Inc.

Board increased to ten directors; Dr. Bello elected as Class II director effective June 10, 2025.
Term expires at 2026 annual meeting; appointed to Nominating and Corporate Governance Committee.
Compensation follows standard non-employee director terms as described in the 2025 proxy statement.
Dr. Bello will enter into the company's standard indemnification agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Akintunde Bello

Class II director

XLO · Xilio Therapeutics, Inc.

Effective: 2025-06-10
Filed: Jun 10, 2025 23:59 UTC

elected Akintunde Bello, Ph.D., as a Class II director of the Company

Source: SEC EDGAR

accession 0001558370-25-008512

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.